Axcan acquires Mpex

Thursday, April 14, 2011

Two pharmaceutical companies, Mpex and Axcan, have entered into an agreement in which Axcan will acquire all of the outstanding shares of Mpex and its lead product candidate, Aeroquin.  An aerosol formulation of levofloxacin, Aeroquin is currently in phase III clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.

[Read More]